Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
256 questions in 49 reviews · Haematology
current versionsNo studies 256 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) Major bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) Major bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Aspirin (ASA) vs direct oral anticoagulants (DOAC) All‐cause mortality ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Aspirin (ASA) vs direct oral anticoagulants (DOAC) Symptomatic deep vein thrombosis ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Aspirin (ASA) vs direct oral anticoagulants (DOAC) Major bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Aspirin (ASA) vs vitamin K antagonist (VKA) Major bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Vitamin D vs placebo or standard care alone Improvement of clinical status · individualswith moderate to severe disease Vitamin D supplementation for the treatment of COVID‐19: a living systematic review (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Vitamin D vs placebo or standard care alone Quality of life, including fatigue and neurological status · individualswith moderate to severe disease Vitamin D supplementation for the treatment of COVID‐19: a living systematic review (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Vitamin D vs placebo or standard care alone Serious adverse events · individualswith moderate to severe disease Vitamin D supplementation for the treatment of COVID‐19: a living systematic review (2021) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs placebo or standard care alone Duration to symptom resolution · people with SARS‐CoV‐2 infection and asymptomatic or mild disease Colchicine for the treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs placebo or standard care alone Quality of life · people with SARS‐CoV‐2 infection and asymptomatic or mild disease Colchicine for the treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Colchicine plus standard care vs standard care (plus/minus placebo) Quality of life, including fatigue and neurological status at longest · people with COVID‐19 and moderate to severe disease Colchicine for the treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs placebo or standard care alone Symptom resolution · people with SARS‐CoV‐2 infection and asymptomatic or mild disease Colchicine for the treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events associated with PET ‐ not reported · Individuals with Hodgkin lymphoma Interim PET‐results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta‐analysis of… (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Enoxaparin vs no enoxaparin Thrombosis‐related mortality ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Enoxaparin vs no enoxaparin Quality of life ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Enoxaparin vs no enoxaparin Asymptomatic venous thromboembolism ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Enoxaparin vs no enoxaparin Adverse events: clinically relevant non‐major bleeding / heparin‐induced thrombocytopenia ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates Major bleeding ‐ not reported · thromboprophylaxis in adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates Quality of life ‐ not reported · thromboprophylaxis in adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates Clinically relevant non‐major bleeding ‐ not reported · thromboprophylaxis in adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Enoxaparin vs no enoxaparin All‐cause mortality ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia (2020) · Cochrane | no estimate extracted | NR | No studies |
MSCs vs control/placebo Health‐related quality of life · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their… Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in… (2019) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic plasma transfusion before surgery/invasive procedures vs alternative haemostatic agents Number of transfusions per participant within 7 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic plasma transfusion before surgery/invasive procedures vs alternative haemostatic agents Number of individuals requiring a transfusion within 7 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic plasma transfusion before surgery/invasive procedures vs alternative haemostatic agents Serious adverse events measured by surgery or procedure‐related complications within 30 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic plasma transfusion before surgery/invasive procedures vs alternative haemostatic agents Quality of life ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | no estimate extracted | NR | No studies |
Thromboelastography threshold vs standard of care (laboratory parameters) All‐cause mortality up to 30 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | no estimate extracted | NR | No studies |
Thromboelastography threshold vs standard of care (laboratory parameters) Number of transfusions per participant within 7 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | no estimate extracted | NR | No studies |
Thromboelastography threshold vs standard of care (laboratory parameters) Serious adverse events measured by surgery or procedure‐related complications within 30 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | no estimate extracted | NR | No studies |
Thromboelastography threshold vs standard of care (laboratory parameters) Quality of life ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic plasma transfusion before surgery/invasive procedures vs no prophylactic plasma transfusion before surgery/invasive procedures (colloid, crystalloid, placebo, or no treatment) Serious adverse events measured by surgery or procedure‐related complications within 30 days ‐ not reported · patients undergoing non‐cardiac surgery or invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic plasma transfusion before surgery/invasive procedures vs no prophylactic plasma transfusion before surgery/invasive procedures (colloid, crystalloid, placebo, or no treatment) Quality of life ‐ not reported · patients undergoing non‐cardiac surgery or invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic plasma transfusion before surgery/invasive procedures vs alternative haemostatic agents All‐cause mortality up to 30 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Polyneuropathies · newly diagnosed, transplant‐ineligible adults with symptomatic multiple myeloma Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults… (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Serious adverse events · newly diagnosed, transplant‐ineligible adults with symptomatic multiple myeloma Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults… (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life · newly diagnosed, transplant‐ineligible adults with symptomatic multiple myeloma Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults… (2019) · Cochrane | no estimate extracted | NR | No studies |
ATRA in addition to chemotherapy vs chemotherapy only Quality of life · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL)) Effects of all‐trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid… (2018) · Cochrane | no estimate extracted | NR | No studies |
Platelet transfusion vs no platelet transfusion All‐cause mortality up to 30 days after the procedure · People with thrombocytopenia Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of… (2018) · Cochrane | no estimate extracted | NR | No studies |
Platelet transfusion vs no platelet transfusion Transfusion‐related complications within 24 hours of the procedure · People with thrombocytopenia Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of… (2018) · Cochrane | no estimate extracted | NR | No studies |
Platelet transfusion vs no platelet transfusion Quality of life (as defined by the individual studies) · People with thrombocytopenia Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of… (2018) · Cochrane | no estimate extracted | NR | No studies |
Nivolumab vs no other intervention Treatment‐related mortality · adults with Hodgkin's lymphoma Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) (2018) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic platelet transfusion prior to surgery vs alternative treatments Mortality secondary to thromboembolism within 30 days of surgery – not reported · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic platelet transfusion prior to surgery vs alternative treatments Mortality secondary to infection within 30 days of surgery – not reported · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR All‐cause mortality within 30 days of surgery – not reported · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Mortality secondary to bleeding within 30 days of surgery – not reported · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Mortality secondary to thromboembolism within 30 days of surgery – not reported · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Mortality secondary to infection within 30 days of surgery – not reported · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic platelet transfusion prior to surgery vs no prophylactic platelet transfusion prior to surgery Mortality secondary to bleeding within 30 days of surgery – not reported · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | NR | No studies |